RXQ Compounding, LLC, Athens, OH

Is RXQ Compounding, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “Out of business”.

Does RXQ Compounding, LLC hold a Ohio pharmacy license?

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

Has RXQ Compounding, LLC had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Jun 6, 2019) for RXQ Compounding, LLC. State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
RXQ Compounding, LLC
Location
Athens, OH
Type as FDA labels it
503B
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 18, 2019
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 14 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as RXQ Compounding, LLC, a 503B facility, with 2 dated actions.

Document
Jun 18, 2019Recall noticeFirm Press Release : RXQ Compounding, LLC Issues Voluntary Nationwide Recall of All Sterile Products within Expiry and Voluntarily Cessation of Production Due to the Lack of Sterility Process Assurance (06/18/2019)FDA copy (archived)
Jun 6, 2019Form 483483 Issued 06/06/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

The dashboard does list RXQ Compounding LLC, Albany, OH (FEI 3011509553): same name and state, different city, so not treated as this site.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 14 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 6, 2019 to Jun 6, 2019: 14 observations

Firm on the cover
RXQ Compounding LLC, 340 W State St Unit 9, Athens, OH 45701-1564
FEI number
3011509553
Establishment type on the cover
503 B Outsourcing Facility
FDA district office on the cover
300 River Place, Suite 5900 Detroit, Mr 48207
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

- There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A. Since August 2017, your finn has conducted approximately eight (8) sterility failure investigations for the following:

Dated

Investigation

Product

Lot Number

Microbial Identification

INV-2019-043

Ascorbic Acid 500ml?/mL

Kocuria rihzovhilla

INV-2019•040

Sodium Bicarbonate 8.4%

Paenibacillus urina/is; Streptococcus oralis; Rothia aeria

INV-2019-034

Procaine HCI 20 ml?/mL

Pending as of 5/30/2019

INV-2019-002

Ascorbic Acid 500 ml?/mL

PeniciJ/ium citrinum

ll/1 9/2018

INV-2018-073

Ascorbic Acid 500 m2/mL

11132018:68, 11132018:43

Baciilus cereus

INV-2018-059

Lidocaine HCI 1%

Bacillus in/antis; Microbacterium liquefaciens/oxy danslmaritypicu m

lNV-2018-043

Lidocaine HCI 1%

Propionibacteriu m (Cutibacterium acnes

INV-2018-025

Phenylep 1.5%Lidocaine I%

Propionibacteriu m acnes; Staphylococcus aureus; Staphylococcus eoidermis

These investigations were incomplete in that they did not include other lots of product potentially impacted, did ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

Specifically,

A . Proper aseptic technique was not practiced by personnel engaged in manufacturing sterile drug products. For example, on 05/07/2019, during the production of Bupivacaine 0.125% I Ropivicaine 0.5%, lots 05072019:88 and 05072019:67, we observed the following:

For example, on 05/07/2019, during the production ofBupivacaine 0.125% I Ropivicaine 0.5%, lots 05072019:88 and 05072019:67, we observed the following:

a. Operators working in a <Redacted B4> laminar flow ISO 5 hood were observed reaching over and blocking first pass air around open containers, either before or after it was filled with sterile product. The filled product containers were not discarded. Additionally, these movements were occurring at a rapid pace.

b. The sterile gowned operator was observed entering the ISO 8 anteroom, ISO 7 clean room, and the non-classified <Redacted B4> using sterile gloves to obtain materials for production such as product containers and environmental monitoring plates. This activity can occur more than 40 times. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

A. The media fill program is deficient in scope and process, for example:

a. Operator qualification media fills are performed in batch sizes of <Redacted B4> however, products are routinely compounded in <Redacted B4> , for example, Ascorbic Acid 500 mg/mL Lot# 12122018:20. Filling of batch sizes greater than <Redacted B4> has not been validated.

b. Operator qualification media fills are performed with <Redacted B4> vials; however, your firm produces compounded drug products in 10 mL, 30 mL, 50 mL and 100 mL vial sizes. Filling of vial sizes other than <Redacted B4> has not been validated.

c. Media fills do not capture the worst-case processing conditions such as the number of operators dispensing product in one hood simultaneously and the number of aseptic manipulations in the hood. For example, bulk drug product is routinely <Redacted B4> This process typically involves <Redacted B4> technicians in the cleanroom.

d. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. <Redacted B4> cleaning of the ISO 5 hoods is performed using <Redacted B4> . The cleaning solution is made in the ISO 7 clean room by mixing the sterile <Redacted B4> with sterile <Redacted B4> in a non-sterile bucket that is stored in the ISO 8 ante room. The bucket is wiped with <Redacted B4> before being transferred into the ISO 7 cleanroom. A sterile lint-free wipe is dipped into the bucket of non-sterile cleaning solution and used to clean the inside of the ISO 5 hoods.

B. Your environmental monitoring identification results show recoveries of spore-forming organisms in the ISO classified spaces, which suggests your cleaning program is not effective. For example:

Date of recovery

Location

Organism Identification

PersonneJ

Bacillus circulans

ISO 7(Bench)

Bacillus kvomiiensis

<Redacted B4> Hood

Bacillus halosaccharavans

ISO 5 <Redacted B4> Hood <Redacted B4> 03/14/2019

Bacillus circu/ans

I j ISO 5 <Redacted B4> Hood

Bacillus narlichenformis

r)(1 04/20/2019

ISO ?(Bench)

Paenibacillius orovencensis

C. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

Environmental monitoring in the cleanrooms and the surrounding supporting clean areas is deficient in that it does not represent the working conditions during multiple steps of processing. For example:

A. Formulation of bulk drug solutions takes place in non-classified areas. On 05/07/2019, we observed the formulation of Bupivicaine 0.125% / Ropivicaine 0.2% Injection Solution lot #05072019:88 in non-classified space.

B. Air and surface sampling is not conducted in the non-classified areas or the cleanrooms during the <Redacted B4> of bulk drug products. On 05/07/2019, we observed the <Redacted B4> of Bupivicaine 0.125% / Ropivicaine 0.2% Injection Solution lot #05072019:88 from non-classified space into the 1S05 hood without any air or surface sampling in the non-classified area ISO 7 cleanroom, or ISO 5 hood while the connection was being made or while the solution was being <Redacted B4>

C. The air and surface sampling locations in the ISO 8, ISO 7, and ISO 5 areas have no rationale to support the chosen locations. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength) quality or purity of the drug product.

Specifically,

The process for cleaning equipment used for batch formulation an <Redacted B4> is not validated to show removal of drug product residue. For example:

A. <Redacted B4> used during <Redacted B4> of drug product is reused. The <Redacted B4> is cleaned as follows: <Redacted B4>, For example; Ascorbic Acid 500 mg/mL lot # 12122018 :20.

B. Mixing <Redacted B4> meant for single-use are reused to <Redacted B4> in the non-classified area for multiple <Redacted B4> batches of drug product such as ascorbic acid and sodium bicarbonate.

C. Stainless steel used for <Redact ed B 4> are purged with <Redacted B4> without any additional steps and stored in the non-classified areas.

(fiJ (4)

D. Stir bars and Juer lock used in bulk formulation are washed with kitchen dish soap, rinsed with deionized <Redacted B4>

Observation 7

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically,

A. Your firm does not initiate change controls when necessary and in a timely manner. For example, according to your quality assurance unit, a change control was not initiated for the decommissioning of <Redacted B4> and the movement of <Redacted B4> from room 215 to room 211 .

B. Your quality control unit failed to initiate an OOS investigation for out of specification product yield in batch records reviewed, for example, Trypan Blue 0.06% lot #01032019:60.

C. Training records are not maintained by the quality assurance unit and are often incomplete. For example, five employee training records were observed to not have been fully completed for tasks related to sterile compounding.

D. Your firm does not follow change controls that are opened to effect change. For example. Change Control 2019-074 opened on 03/04/2019 and closed on 04/18/2019 addressed using <Redacted B4> for the <Redacted B4> ,of drug products. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, time limits for sterile drug production have not been established or evaluated to demonstrate that preparing and holding drug products in unclassified areas is acceptable to assure the quality of finished sterile drug products. For example, Ascorbic Acid 500mg/mL lot #12122018:20 was prepared and mixed ol <Redacted B4> , it was then left in the non­classified area until filling operations resumed on <Redacted B4> This lot was released for sale. Your firm has not provided any scientific evidence to justify the use of a <Redacted B4> hold time to produce sterile drug products that are held and stored in the non-classified areas prior to being <Redacted B4> and filled in the ISO 5 hood.

Observation 9

Employees engaged in the manufacture, processing, packing and holding of a drug product lack the training required to perform their assigned functions.

Specifically,

A. Members of the quality assurance unit lack the proper qualifications for their job duties. For example, there is no documented training for a quality control technician who is responsible for lot release, batch record review, overseeing the media fill program, and overseeing the environmental monitoring program. This technician reviewed and released PHEN 10% CY CLO 1 % TROP 1 % KETO 0.5% OPTH lot #03142019:95 for distribution.

B. There is no docwnented training for the pharmacist in charge who has been employed by your firm for approximately one year and in this role since November 2018.

C. Visual inspection training does not include a challenge set that operators must pass in order to be qualified to inspect products. Additionally, all product types are not used to train employees and it is left up to the technicians to admit proficiency amongst various container types during the visual inspection process.

D. ...

Read the full 483 (PDF on fda.gov)

Observation 10

The number of qualified personnel is inadequate to supervise the manufacture, processing, packing and holding of each drug product.

Specifically, the quality unit is inadequately staffed to keep up with the pace of production. For example, there is currently one quality unit member responsible for all out of specification and complaint investigations. In 2019, there have been more than 75 out of specification results obtained, each requiring an investigation.

THIS IS A REPEAT OBSERVATION

Observation 11

Laboratory controls do not include a determination of conformance to appropriate specifications for drug products.

Specifically.

A. Drug products produced at your facility do not have specifications, when appropriate, for preservative content, visible particles, or sub-visible particles.

B. Endotoxin specifications for each drug product are not established by your firm. Pharmacists enter the maximum patient dosage infonnation at the time of sample submission to determine the endotoxin limit. The dosage \\' entered is at their discretion and is not standardized. For example, Methylcobalamin IO mg/mL lot O 1022019:53.

~'\ MA "-c I l}C.• /2.o tct

Observation 12

Routine checking of mechanical equipment is not performed according to a written program designed to assure proper performance.

Specifically,

A. The <Redacted B4> scale in room 213 has not been qualified for use, and Deviation DV-2019-007 states that the scale should be verified <Redacted B4> This verification is not recorded on Log 0 I 7 LUMAC -Log of Use, Maintenance, and Cleaning for this equipment. As of 05/03/2019, approximately ti lots used materials that were weighed using this unqualified and unverified scale.

B. The <Redacted B4> temperature and humidity monitoring system data loggers have a maximum read temperature of 215F, however, validated <Redacted B4> for <Redacted B4> is Kb <Redacted B4> .

Observation 13

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the quarantine storage of drug products prior to release.

Specifically,

Released and quarantined drug products were observed stored in the same refrigerator or storage rooms, for example:

A. On 05/06/2019, we observed quarantined and released drug products stored in the same refrigerator #0051 located in the gowning room.

B. On 05/06/2019, we observed boxes of quarantined product that were stopped from being shipped due to an out of specification test result stored in room 134d with released product.

Furthermore, there have been at least four customer complaints that addressed product mix-ups.

Observation 14

The container labels of your outsourcing facility's drug products are deficient.

Specifically, your containers do not include the directions for use, including, as appropriate, dosage and administration. -

Examples of your container labels that do not contain this information.

Ascorbic Acid 400mg/mL Injection Solution

Pyridoxine (MDV) 100 mg/mL Injectable Solution

Magnesium Chloride Hexahydrate (PFV) 20% INJ SOLN

Buffered Lidocaine HCL (PF) 1 % Injection Solution (PF)

Ascorbic Acid 500 mg/mL (Non-Com) INJ SOLN (MDV)

Edetate Calcium Disodium 150mg/mL Injectable

Dexpanthenol 250mg/mL (MDV) Injection Solution

Vitamin B Complex 100 (PFV) Injection Solution

Sodium Bicarbonate 8.4% (1 mEq/mL) INJ SOLN

State board of pharmacy records

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.